MPC Therapeutics is focused on developing innovative drugs that target mitochondria, which are essential for cellular energy production and play a critical role in various biological processes. Their lead compounds are designed to enhance the proliferation of stem cells, particularly for T cell therapies, which are crucial in cancer treatment. The company has developed a new generation of mitochondrial modulators, specifically Mitochondrial Carrier Inhibitors, which interfere with the Mitochondrial Pyruvate Carrier (MPC) to optimize energy production and metabolism within cells. This approach is particularly promising for improving the efficiency and durability of CAR T-cell therapies, which are currently limited in their effectiveness against solid tumors.

In addition to their work on CAR T-cell therapies, MPC Therapeutics is exploring the potential of their compounds in regenerative medicine. Their research indicates that modulating pyruvate entry into mitochondria can promote stem cell differentiation, which may have significant implications for treating neurodegenerative diseases and facilitating tissue regeneration. The company is also investigating other mitochondrial targets to further enhance their drug discovery efforts, aiming to leverage mitochondrial activity modulation for a broader range of immune diseases and regenerative applications. Through their patented research and collaborations, MPC Therapeutics is positioning itself as a leader in the field of mitochondrial science and its therapeutic applications.

Switzerland

MPC Therapeutics is a biotechnology company focused on cellular rejuvenation to fight cancer & degenerative pathologies. They develop a class of compounds with applications in immunotherapy and metabolic diseases. The company is founded on the belief that they can manipulate cell behavior to fight cancer and degenerative diseases.

MPC Therapeutics

Company Details